FAQ on Tonix Pharmaceuticals' Presentation at World Vaccine Congress Washington 2025

What is Tonix Pharmaceuticals presenting at the World Vaccine Congress Washington 2025?

Tonix Pharmaceuticals will deliver an oral presentation and lead a panel discussion, details of which will be made available under the Scientific Presentations section of its website following the event.

When and where is the World Vaccine Congress Washington 2025 taking place?

The congress is scheduled for April 22–24, 2025, in Washington, D.C.

What is TNX-102 SL, and why is it significant?

TNX-102 SL is a product candidate for the management of fibromyalgia, having completed two statistically significant phase 3 studies and received FDA Fast Track designation, indicating its potential to address an unmet medical need more quickly.

How can I view Tonix Pharmaceuticals’ presentation after the event?

The presentation will be available under the Scientific Presentations section of Tonix Pharmaceuticals’ website, accessible via www.TonixPharma.com.

What other developments are part of Tonix Pharmaceuticals’ portfolio?

Tonix’s portfolio includes TNX-1300 for cocaine intoxication with Breakthrough Therapy designation, TNX-1500 for preventing allograft rejection and treating autoimmune diseases, and commercial products like Zembrace® SymTouch® and Tosymra® for migraine treatment.

Where can I find the latest news and updates about Tonix Pharmaceuticals?

Updates are available in the company’s newsroom at https://ibn.fm/TNXP.

What is the significance of the FDA Fast Track designation for TNX-102 SL?

The Fast Track designation facilitates the development and expedites the review of drugs that treat serious conditions and fill an unmet medical need, potentially bringing TNX-102 SL to patients sooner.

Who can I contact for more information about Tonix Pharmaceuticals?

For more information, visit Tonix Pharmaceuticals’ official website at www.TonixPharma.com.